Concentra will acquire the firm for $.36 per share in cash in a deal that was approved by Elevation Oncology's board.

The drug is already approved in the EU for transthyretin amyloidosis with polyneuropathy but now covers patients with cardiomyopathy.

Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...

Trump administration health officials assured drugmakers and researchers at a roundtable hosted by the FDA that they want to ...

As with the drug's 2023 approval in castration-resistant tumors, it's not clear if it works comparably in all homologous ...

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

Due to financial, logistical, and regulatory barriers, only two in 10 patients eligible for CAR T-cell therapy in the US ...

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...